Amivantamab 350mg/7mL (50mg/mL) Injection$1,160.00
1–9 boxes
$1,160.00 each
10–24 boxes
8% off
25+ boxes
10% off
Amivantamab 350mg/7mL (50mg/mL) Injection
SKU GME1495Oncology Care
Product Introduction
Amivantamab 350mg/7mL (50mg/mL) is a targeted antibody treatment for selected advanced non-small cell lung cancers with EGFR alterations. Treatment selection depends on tumour testing and the combination regimen being used.
How to use
It is diluted and given by intravenous infusion. The first dose is divided across two days, with premedication and careful observation for infusion-related reactions.
How it works
The antibody binds EGFR and MET receptors, blocks growth signalling and helps immune cells identify and destroy tumour cells.
Side effects
Rash, nail inflammation, mouth sores, swelling and tiredness can occur. Infusion reactions and inflammation of the lungs are important risks.
Important information
Report new breathlessness or a worsening cough promptly. Sun protection and early skin and nail care help manage treatment-related skin problems.
Uses
- EGFR-altered advanced non-small cell lung cancer in selected treatment regimens.
Benefits
Targets receptor pathways driving susceptible lung cancers and can improve disease control in a molecularly selected population.
Why is a tumour mutation test needed?
The result establishes whether the cancer has an EGFR alteration for which the treatment regimen is appropriate.
Why is the first infusion split over two days?
Splitting the initial dose and using premedication helps manage the high first-infusion reaction risk.
Are skin changes related to how the medicine works?
Yes. EGFR is also present in normal skin, so blocking it can produce rash and nail-fold inflammation.
Is this an ordinary chemotherapy medicine?
It is a targeted antibody. Some regimens combine it with chemotherapy or another targeted treatment.
EGFR: a receptor that can drive tumour growth. MET: another growth-signalling receptor. NSCLC: non-small cell lung cancer.; AR: Amivantamab 350mg/7mL (50mg/mL) حقن; FR: Amivantamab 350mg/7mL (50mg/mL) injection; PT: Amivantamab 350mg/7mL (50mg/mL) injeção; ES: Amivantamab 350mg/7mL (50mg/mL) inyección; RU: Amivantamab 350mg/7mL (50mg/mL) инъекция; ID: Amivantamab 350mg/7mL (50mg/mL) suntikan; VI: Amivantamab 350mg/7mL (50mg/mL) thuốc tiêm; MS: Amivantamab 350mg/7mL (50mg/mL) suntikan; TL: Amivantamab 350mg/7mL (50mg/mL) iniksyon; ZH-SG: Amivantamab 350mg/7mL (50mg/mL) 注射剂